Servicio Autónomo Instituto de Biomedicina, Universidad Central de Venezuela, Caracas, Venezuela; Servicio Autónomo Instituto de Biomedicina, Ministerio del Poder Popular para la Salud, Venezuela.
Servicio Autónomo Instituto de Biomedicina, Ministerio del Poder Popular para la Salud, Venezuela.
Int J Infect Dis. 2022 Sep;122:850-854. doi: 10.1016/j.ijid.2022.06.008. Epub 2022 Jun 8.
Scarce information is available regarding the long-term immunogenicity of the Sputnik V vaccine. Here Sputnik V vaccinated subjects were evaluated 6 months after receiving the 2-dose prime-boost schedule.
Eighty-six hospital workers from Venezuela, 32 with a previous COVID-19 infection and 54 SARS-CoV-2 naïve subjects, were enrolled. IgG antibodies levels against the wild-type Receptor Binding Domain (RBD) were measured in an ELISA and with an in vitro ACE2-surrogate RBD binding inhibition assay at day 42 and day 180 after receiving the second dose. IgG levels were expressed in BAU/ml. Binding inhibition antibodies were expressed in IU/ml.
On average, RBD-IgG levels decreased by approximately 50% between the two time-points in the COVID-19 naïve cohort (geometric mean concentration (GMC) 675 BAU/mL vs. 327 BAU/ml) and decreased by approximately 25% in the previously infected cohort (GMC 1209 BAU/mL vs 910 BAU/ml). Within our cohort, 94% showed a "good to excellent" neutralizing activity measured with the in vitro test 6 months after vaccination.
The Sputnik V vaccine provided long-term and durable humoral immunity in our cohort specially if a person has been both vaccinated and had a previous infection with SARS-CoV-2.
关于卫星 V 疫苗的长期免疫原性，信息稀缺。在此，对接受两剂基础-加强免疫方案接种的卫星 V 疫苗接种者进行了 6 个月后的评估。
委内瑞拉的 86 名医院工作人员参与了这项研究，其中 32 人有既往 COVID-19 感染史，54 人 SARS-CoV-2 初免。在接种第二剂后第 42 天和第 180 天，通过 ELISA 和体外 ACE2 替代 RBD 结合抑制试验，测量针对野生型受体结合域（RBD）的 IgG 抗体水平。IgG 水平以 BAU/ml 表示。结合抑制抗体以 IU/ml 表示。
在 COVID-19 初免队列中，RBD-IgG 水平在两个时间点之间平均下降了约 50%（几何平均浓度（GMC）675 BAU/ml 与 327 BAU/ml），在既往感染队列中下降了约 25%（GMC 1209 BAU/ml 与 910 BAU/ml）。在我们的队列中，94%的人在接种后 6 个月的体外试验中表现出“良好到极好”的中和活性。
在我们的队列中，卫星 V 疫苗提供了长期和持久的体液免疫，特别是如果一个人既接种了疫苗，又曾感染过 SARS-CoV-2。
